Castle Biosciences Inc (CSTL) News

Castle Biosciences to Host Second Annual Castle Cares Charity Walk

Castle employees to raise funds and awareness for five partner organizations in support of patients impacted by skin cancer, esophageal cancer...

Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year

Castle also earns national recognition through five Top Workplaces Culture Excellence Awards — Innovation, Work-Life Flexibility, Compensation...

Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data on...

Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology

Data shows testing with DecisionDx®-Melanoma provided significant prognostic information regarding survival outcomes Castle Biosciences, Inc...

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on...

Castle Biosciences Presents New Data Demonstrating the Ability of DecisionDx®-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging

Data shared during the 2023 Fall Clinical Dermatology Conference for PAs & NPs® Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational Dermatology

Treatment algorithm can assist clinicians in tailoring their care for patients with high-risk cutaneous squamous cell carcinoma (cSCC) based on...

Current Report Filing (8-k)

0001447362FALSE00014473622023-06-052023-06-05UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-KCURRENT REPORTPursuant...

Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new...

Current Report Filing (8-k)

IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder

In the study, patients whose medication management was guided by IDgenetix achieved a 35% increase in medication response and a 64% increase in...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...